Miami, Florida — Cellgenic, the biologics manufacturing division of Global Stem Cells Group (GSCG), today announced that its advanced biologics manufacturing facility in Cancún, Mexico, has officially commenced full operations. Following its initial introduction to the international medical community during the ISSCA Global Regenerative Medicine Summit in September 2025, the laboratory is now actively producing and distributing biologic products to authorized medical professionals and institutions in international markets where local regulations permit.

The operational launch represents an important step in what Cellgenic hopes will be a long-term effort to support responsible access to regenerative biologics through transparent manufacturing processes, ethical sourcing, and internationally guided quality practices.

Purpose-Built Facility Designed for International Distribution

The Cancún laboratory was designed as a centralized manufacturing hub intended to support physicians, clinics, wellness centers, and research institutions seeking access to advanced biologics. The facility incorporates modular cleanroom environments, controlled cold-chain logistics, structured batch documentation, and donor traceability systems developed with reference to AATB-aligned practices and COFEPRIS-guided operational frameworks.

To Cellgenic’s knowledge, this facility is the first in Cancún developed specifically for the external manufacturing and distribution of biologics, rather than production limited to internal or single-site clinical use.

Xeno-Free Manufacturing Philosophy

All biologics produced at the Cancún facility are manufactured under xeno-free conditions, meaning that no animal-derived components are used at any stage of production. Cellgenic’s manufacturing philosophy emphasizes the use of human-origin materials, controlled inputs, and documented sourcing processes.

While Cellgenic does not make claims regarding clinical outcomes, the company believes that xeno-free manufacturing practices may support broader international acceptance and alignment with evolving regulatory expectations in multiple regions. The company hopes that this approach will offer physicians and institutions additional confidence when evaluating biologics for educational, investigational, or authorized clinical use.

Integration with Cellular Hope Institute and ISSCA

The facility operates in close coordination with the Cellular Hope Institute, a clinical and educational center operating under Global Stem Cells Group. based in Cancún, as well as with ISSCA (International Society for Stem Cell Application), the educational division of Global Stem Cells Group.

Through this integration, visiting physicians and researchers participating in ISSCA-accredited programs may observe manufacturing workflows, engage in hands-on educational sessions, and participate in structured clinical discussions related to biologics handling and responsible application.

“We expect this facility to play a meaningful role in our integrated model of manufacturing, education, and clinical collaboration,” said Sarah Barroso, Managing Director of Cellgenic. “By aligning our laboratory operations with the Cellular Hope Institute and ISSCA’s educational platform, we hope to contribute to greater transparency, consistency, and professional dialogue within the regenerative medicine field.”

Current Manufacturing Capabilities and Pipeline Development

As of January 2026, the Cancún facility is producing the following biologics for authorized distribution:

• Exosome Flow Series – Liquid exosomes available in multiple concentrations
• Lyophilized Exosomes – Prepared for topical and localized applications
• Umbilical Cord–Derived Mesenchymal Stem Cells (MSCs) – Cryopreserved and culture-expanded
• Natural Killer (NK) Cells – Produced under controlled freezing and handling protocols
• Allogeneic Fibroblasts – Intended for aesthetic and research-oriented applications
• Sterile Diluents – Including bacteriostatic water and saline solutions

Cellgenic has also outlined plans to expand its capabilities during 2026 to include:

• Exosome–peptide combination formulations
• Multi-peptide blended delivery formats
• Cell-free conditioned media (secretome)
• Cryopreserved cell banking services
• Private-label and white-label manufacturing programs

All products are accompanied by batch documentation, donor screening records, and handling guidelines. Cellgenic emphasizes that its biologics are not intended to diagnose, treat, cure, or prevent any disease and are supplied exclusively to authorized professionals and institutions in compliance with local regulations.

Commitment to Responsible Global Expansion

As part of its international growth strategy, Cellgenic has introduced an Authorized Distributor Program designed for qualified partners operating in compliant markets. The program is structured to support long-term collaboration through educational resources, standardized documentation, and regional alignment initiatives.

“We believe this facility reflects our continued focus on responsibility, quality, and long-term infrastructure,” said Dave Christensen, CEO of Global Stem Cells Group. “Our goal has never been rapid expansion without structure. We hope this laboratory will support physicians and institutions seeking consistent, well-documented biologics produced under carefully designed conditions.”

About Cellgenic

Cellgenic is the biologics manufacturing and innovation division of Global Stem Cells Group, a multinational organization engaged in regenerative medicine education, clinical collaboration, and biologics development. With operations and partnerships across North America, Latin America, Europe, and Asia, Cellgenic focuses on producing biologics under transparent, xeno-free, and compliance-oriented frameworks to support responsible use in diverse international settings.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to the operational launch and expansion of capabilities at our Cancún, Mexico biologics manufacturing facility. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. 

Miami, Florida – Global Stem Cells Group (GSCG) and its educational division, the International Society for Stem Cell Application (ISSCA), have successfully concluded two major events in their 2025 international educational series: the International Regenerative Medicine Conference in Bogotá, Colombia, and the International Regenerative Medicine Conference and Certifications in Cancún, Mexico.

Both gatherings brought together physicians, researchers, and healthcare professionals from across the world to exchange knowledge and explore the latest advancements in regenerative medicine, cellular therapies, and peptide science. With these two conferences, ISSCA has now held more than twelve international conferences so far this year, reaffirming its ongoing commitment to physician education, scientific collaboration, and the responsible advancement of regenerative technologies.

---

Conference and Scientific Highlights from Colombia

The Bogotá Conference was held on October 24–25, 2025, at the W Hotel, featuring a comprehensive scientific agenda developed by the ISSCA Scientific Committee. International experts presented cutting-edge topics such as exosomes, peptides, NAD+, and MUSE cells.

Distinguished speakers included Lauren Fitzgerald, MD (USA), on peptide-based clinical optimization; Brandon Sassouni, MSc (USA), on MUSE cells and exosome therapeutics; Andrea Lapeire, MD (Argentina), ISSCA LATAM Director; Richard Silva, DO (USA), on functional regenerative applications; and Rafael Moguel, MD (Mexico), on cardiovascular regeneration.

The conference concluded with MedConnect, ISSCA’s signature international networking cocktail event, featuring an upscale social experience with canapés, beverages, live music, and performance showcases, while fostering high-level collaboration between physicians, researchers, and regenerative medicine organizations worldwide.

---

Conference and Certifications in Cancún

From November 7–9, 2025, ISSCA and GSCG hosted the International Regenerative Medicine Conference in Cancún at the InterContinental Presidente Cancún Resort, followed by three specialized certification programs:

1. Stem Cell Therapies Certification – covering clinical applications of mesenchymal and MUSE cells, exosome integration, and regenerative treatment protocols.
   
   
2. Advanced Peptide Certification – focused on molecular mechanisms, clinical design, and patient-oriented peptide protocols for longevity, performance, and metabolic balance.
   
   
3. MSK / Sports Medicine Certification – emphasizing regenerative techniques for orthopedic and sports-related injuries, including PRP, exosome, and peptide-based recovery strategies.
   
   

Keynote presentations were delivered by Greg Jones, NMD, ABAAHP (USA) on peptide-based preventive medicine; Jason Pencek, DC, FNP (USA) on mitochondrial repair and integrative peptide strategies; Prof. Dr. Roni Moya (Portugal) on immune engineering and translational applications; Márcio Kume, MD, PhD (Brazil) on musculoskeletal regeneration and orthopedic innovation; Wajid Burad, MD (Mexico) on sports performance and non-surgical interventions; and Brandon Sassouni, MSc (USA) on advancements in universal cell applications.

“These programs are designed to provide physicians with practical, evidence-based tools that they can apply directly in their medical practice,” said Benito Novas, Founder of ISSCA. “We believe that combining scientific discussion with structured certifications ensures a more complete and responsible approach to regenerative medicine education.”

Dave Christensen, CEO of Regenerative Medical Technology Group Corp. (parent to GSCG), added:

“The participation and engagement seen in both Colombia and Cancún demonstrate the strong interest among physicians in expanding their knowledge in regenerative and peptide-based medicine. These events continue to strengthen the foundation for ongoing collaboration between science and clinical practice.”

---

Upcoming Educational Events

Before the end of the year, ISSCA and GSCG will continue their educational calendar with two additional international conferences:

• Lima, Peru – November 28–30, 2025
  
  
• San Juan, Puerto Rico – December 5–6, 2025
  
  

Both upcoming conferences will maintain the organization’s multidisciplinary format, combining theoretical lectures, certification modules, and hands-on workshops covering stem cell therapy, peptide applications, and musculoskeletal repair.

Looking ahead, Global Stem Cells Group and ISSCA are preparing a robust educational program for 2026, which already includes events in more than 15 countries across Latin America, Europe, the Middle East, and Asia. The goal is to continue facilitating responsible scientific education, networking, and professional development for physicians dedicated to regenerative and cellular medicine.

---

About the International Society for Stem Cell Application (ISSCA)

ISSCA, a division of Global Stem Cells Group, focuses on education, certification, and professional development in regenerative medicine and cellular therapies. With over 15 years of global experience, ISSCA designs and delivers multidisciplinary programs that connect scientific innovation with real-world clinical application.

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is an international organization dedicated to advancing regenerative medicine through research, product development, and physician education. The company provides access to the latest biologic innovations, clinical tools, and specialized training to support the safe and effective practice of regenerative therapies.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida —CELLGENIC, a division of Global Stem Cells Group and a recognized name in regenerative medicine, is pleased to announce the successful introduction of its Peptide Pen product line, officially presented during the Global Stem Cells Group Global Summit held in Cancún. The new line represents an important step toward simplifying and modernizing peptide therapy within the field of regenerative and longevity medicine.

The CELLGENIC Peptide Pen series was designed to offer physicians a more practical approach to peptide therapy. Each pre-loaded device contains synergistic peptide formulations that we believe may support various clinical goals such as recovery, immune balance, metabolic optimization, and overall wellness. By integrating multiple compounds into a single, ready-to-use pen, we hope to help physicians streamline their protocols while maintaining consistency and ease of use.

“Our mission has always been to make advanced biologics more accessible and clinically practical,” said Benito Novas, Founder of Global Stem Cells Group. “We believe the Peptide Pen line reflects this philosophy by providing a convenient and reliable tool for physicians dedicated to regenerative and performance medicine.”

Since its debut at the Global Summit, the Peptide Pen line has received encouraging interest from physicians attending the event and from CELLGENIC’s international partners. The company believes this positive reception reflects the growing recognition of peptide-based approaches within medical practice.

“We are very encouraged by the response from physicians who attended the Summit,” said Sarah Barroso, Managing Director of CELLGENIC. “We expect the Peptide Pen to continue generating interest among professionals seeking innovative yet practical tools to integrate into their existing clinical programs.”

---

A Growing Movement in Modern Medicine

Across the world, peptide therapy is gaining attention among physicians who seek to work at the intersection of biology, longevity, and personalized medicine. These short chains of amino acids are being studied for their potential roles in supporting cellular repair, optimizing metabolism, and promoting balanced physiological function.

At CELLGENIC, we believe peptide therapy represents one of the most promising frontiers in the evolution of regenerative and preventive medicine. As healthcare continues to shift toward individualized and performance-based care, peptide integration may help physicians design more targeted and adaptive therapeutic programs.

Through innovation and education, we hope to contribute to this global movement by offering tools that are practical, well-supported, and aligned with responsible medical practice.

---

Commitment to Education and Ethical Practice

The launch of the Peptide Pen line also aligns with CELLGENIC’s ongoing educational mission through the International Society for Stem Cell Application (ISSCA), which continues to promote physician training in advanced biologic and peptide-based therapies.

CELLGENIC sells its products exclusively to licensed physicians and medical professionals, ensuring that all peptide applications remain within a qualified and ethical clinical framework.

Through this initiative, CELLGENIC continues to expand its presence in regenerative medicine, maintaining a focus on innovation, education, and international collaboration.

---

About CELLGENIC

CELLGENIC, a division of Global Stem Cells Group, focuses on the development and distribution of advanced biologic products including exosomes, cell-based systems, and peptide solutions. With more than 15 years of experience, CELLGENIC aims to support physicians worldwide through innovation, training, and reliable access to next-generation medical technologies.

About Global Stem Cells Group and CELLGENIC

Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with a presence in more than 40 countries. The organization brings together clinical research, physician education, and biologics development under one umbrella.

Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, and platelet-rich plasma kits—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.

Global Stem Cells Group is a subsidiary to our publicly traded company, Regenerative Medical Technology Group Inc., operating under the symbol RMTG.

More information:

www.stemcellsgroup.com | www.issca.us

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to expansion efforts into the Dominican Republic. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Cancún, Mexico — September 14, 2025. The Regenerative Medicine Global Summit 2025, organized by the International Society for Stem Cell Application (ISSCA) — the world’s largest organization dedicated to training physicians in regenerative medicine — successfully took place on September 12–13 at Secrets The Vine Cancún.

With a full house of participants from more than 30 countries, including representatives from Malaysia, Vietnam, Tajikistan, Ghana, South Africa, Japan, the United States, Spain, Italy and multiple nations, Cancún became the epicenter of innovation and collaboration in regenerative medicine.

---

Leadership Reflections

“This summit proved that regenerative medicine is no longer confined by borders. With physicians and scientists gathered from every continent, we are setting a global standard in how knowledge is shared and therapies are advanced,”
 — Dave Christensen, CEO of Global Stem Cells Group (GSCG)

“Our goal is to close the gap between research and clinical practice, giving physicians the tools to deliver the medicine of tomorrow, today. This summit is not only about science; it is about shaping a healthier future for patients,”
 — Benito Novas, Founder of ISSCA

“With participants from more than 30 countries, Cancún truly became a hub of regenerative medicine. Between the scientific sessions, the workshops, and the networking opportunities, this event proved Mexico’s growing leadership in biotechnology and medical education,”
 — Sarah Barroso, Managing Director, CELLGENIC

---

Day 1: Scientific Conferences

The first day offered a full agenda of keynote lectures, where global experts presented disruptive insights into the future of regenerative medicine:

• Prof. Mari Dezawa (Japan): MUSE Cells™ and Their Exosomes: The Next Frontier in Immune-Modulating Therapies
  ING Agenda Cancun SUMMIT CORT
  
  
• Dr. Rafael González (USA): Beyond the Hype: The Real-World Evidence Behind NK Cells and Stem Cell Therapies
  
• Dr. Matt Cook (USA): Precision Ultrasound-Guided Interventions
  
  
• Dr. Alan Gaveck (USA): Engineering the Immune System: From Lab to Clinic
  
  
• Jason Pencek (USA): Next-Gen Biohacking: Cellular Strategies for Repair, Performance & Healthspan
  
  
• Prof. Dato’ Sri Dr. Mike Chan (Malaysia/Europe): Bioregenerative Longevity and Immunomodulation in Anti-Aging Medicine
  
• Dr. Keith L. March (USA): The Rise of Cell-Free Regenerative Therapies: Clinical-Grade Secretomes as the Future of Medicine
  
• Dr. Greg Jones (USA): Peptides, Hormones, and Functional Protocols to Reverse Chronic Degeneration
  
• Dr. Richard Silva (USA): Sports Optimization with Cellular Medicine
  
• Dr. Jeff Wiegers (USA): Pain Management Reimagined: Biologics, Peptides, and Guided Injections
  
• Dr. Vincenzo Di Donna (Italy): Organoids and Regenerative Ozone Therapy to Support Stem Cell Therapy
  
• Prof. Roni Moya (Portugal): Innovations in Regenerative Biomedicine
  
• Prof. Jonathan Lakey (USA): Advances in Cellular Transplantation
  
• Dr. Matthew Halpert (USA): Cancer as an Immunological Disorder: A New Weapon in the Fight
  

The program also featured a select exhibitor area with booths from CELLGENIC, Eleve Health, Immunocine, Cellular Hope Institute, MUSE Cells Innovation, and ISSCA, allowing participants to discover new therapies, devices, and upcoming opportunities.

The day concluded with MedConnect, ISSCA’s signature networking event, hosted at the rooftop of Royalton Chic Cancún. This gathering allowed physicians to connect with peers in their field and foster collaborations in an exclusive setting overlooking the Caribbean.

---

Day 2: Hands-On Workshops and Certifications

The second day was exclusively reserved for 150 certified participants, divided into five simultaneous workshops designed for practical, hands-on training:

1. MUSE Cells Innovation — Prof. Mari Dezawa, Dr. Jeff Wiegers, and Prof. Jonathan Lakey led a session comparing MUSE Cells with mesenchymal stem cells, exploring applications in orthopedics, aesthetics, and immunology.
   
   
2. NK Cells & Advanced Cellular Therapies — In collaboration with ImmunoSyn at ReHealth’s laboratory, guided by Dr. Rafael González and Dr. Matthew Halpert. Participants later visited the Cellgenic laboratory to observe stem cell manufacturing processes.
   
   
3. Peptide Therapy Workshop — Jason Pencek and Dr. Greg Jones conducted a comprehensive workshop on therapeutic peptides, dosing strategies, and protocols for longevity, aesthetics, and chronic degeneration.
   
   
4. Musculoskeletal & Sports Medicine — Directed by Dr. Richard Silva, Dr. Wahid Burad, and Dr. Vincenzo Di Donna, focusing on sports optimization, musculoskeletal regeneration, and longevity protocols.
   
   
5. Advanced Aesthetics — Presented by Prof. Roni Moya and Prof. Mike Chan, covering exosomes, peptides, PRP, and regenerative aesthetic therapies for facial rejuvenation and tissue regeneration.
   
   

---

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a global organization with over 15 years of experience promoting education, research, and certification in regenerative medicine. With presence in more than 20 countries, ISSCA drives the professionalization of the field through international summits, academic programs, and clinical alliances.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – Global Stem Cells Group (GSCG), an international organization dedicated to advancing regenerative medicine, is pleased to announce what it expects will be the expansion of its CELLGENIC brand into the Dominican Republic. This development is viewed as an important step in GSCG’s broader efforts to make advanced biologics and physician training increasingly accessible across Latin America and the Caribbean.

A Strategic Expansion in the Caribbean

Through this agreement, CELLGENIC hopes to introduce its exosome products and mesenchymal stem cell (MSC) therapies to the Dominican Republic, with the expectation of gradually expanding its product line to include additional advanced cellular therapies. This initiative is also expected to be supported by education and certification programs for physicians, so that the use of regenerative medicine technologies may be carried out responsibly and in line with international best practices.

“We are hopeful that extending CELLGENIC’s presence into the Dominican Republic will represent another meaningful step toward our mission,” said Benito Novas, CEO of Global Stem Cells Group and founder of CELLGENIC. “Our aim is to provide physicians with access to promising biologics alongside educational opportunities. By working closely with our local partners, we expect to help create an environment where regenerative medicine may continue to grow in a safe and ethical way.”

Local Leadership and Collaboration

The rollout in the Dominican Republic will be guided by Dra. Patria González, CELLGENIC’s official representative in the country. Together with her partners, Dr. Faddis Will and Irma Sánchez, Dra. González will support the introduction of CELLGENIC products to the local market.

“After years of development, we are excited about the opportunity to bring CELLGENIC products to physicians and patients in the Dominican Republic,” said Dra. González. “We believe strongly in the potential of regenerative medicine and we hope that exosomes, MSCs, and other advanced therapeutics will become important tools in our local healthcare system. Our expectation is that this collaboration will allow us to do so in alignment with international standards.”

Education at the Core

In addition to product introduction, ISSCA—the educational division of GSCG—plans to organize certification programs to support physicians in their training and clinical application of these protocols.

“Beyond the products themselves, we hope to make education a central part of this initiative,” added Novas. “We expect that properly trained physicians will be able to evaluate and apply these therapies in ways that may benefit their patients.”

Looking Ahead

As part of this collaboration, CELLGENIC and ISSCA will support the upcoming ISSCA 2026 event in the Dominican Republic, scheduled for the first quarter of 2026. The event is anticipated to bring together international experts, local physicians, and healthcare leaders to discuss new opportunities for regenerative medicine in the Caribbean.

“We are hopeful that this partnership will open the door to innovation in our country,” added Irma Sánchez. “The Dominican Republic is not only a beautiful place but also a healthcare market that we believe is ready to explore these possibilities. We expect that physicians and patients alike will benefit from the knowledge and products introduced through this collaboration.”

About Global Stem Cells Group and CELLGENIC

Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with a presence in more than 40 countries. The organization brings together clinical research, physician education, and biologics development under one umbrella.

Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, and platelet-rich plasma kits—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.

Global Stem Cells Group is a subsidiary to our publicly traded company, Regenerative Medical Technology Group Inc., operating under the symbol RMTG.

More information:
www.stemcellsgroup.com | www.issca.us

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to expansion efforts into the Dominican Republic. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – Global Stem Cells Group (GSCG), an international organization focused on advancing regenerative medicine, is pleased to announce what it expects will be the expansion of its operations into Brazil through a new strategic representation agreement with Julius Ladeira. This collaboration is anticipated to bring the full scope of GSCG’s divisions—including ISSCA (International Society for Stem Cell Application) and CELLGENIC, its biologics manufacturing arm—into one of the most dynamic healthcare markets in Latin America.

A New Chapter for Regenerative Medicine in Brazil

Brazil, home to more than 600,000 physicians, has long been recognized as a country with significant potential for regenerative medicine. It is estimated that nearly 50,000 physicians are already engaged in preventive and regenerative practices, with approximately 30,000 incorporating these approaches into their daily work. GSCG believes that the introduction of its educational programs, biologic products, and network of centers of excellence may help align Brazil more closely with the latest global developments in cellular therapies.

“We are hopeful that this new representation will mark the beginning of a long-term partnership that benefits both physicians and patients in Brazil,” said Benito Novas, CEO of Global Stem Cells Group, Founder of ISSCA and CELLGENIC. “For years, many Brazilian physicians have traveled abroad to train with ISSCA and to access advanced technologies. Now, we expect to bring these opportunities directly into the country, creating local access to training, certification, and biologic solutions.”

Local Leadership for National Impact

The agreement appoints Julius Ladeira as the official representative of Global Stem Cells Group in Brazil. He will oversee the introduction of ISSCA educational programs, CELLGENIC’s biologic products, and GSCG’s broader initiatives into the local market.

“It is with great satisfaction that we welcome ISSCA, CELLGENIC, and the Global Stem Cells Group into Brazil,” said Julius Ladeira. “We expect this partnership to be of great importance not only for the Group but also for Brazil as a whole. Our market has extraordinary potential, and we believe this initiative may bring real opportunities for growth and collaboration.”

Upcoming Conference in São Paulo

As part of this expansion, ISSCA has already scheduled its first major educational event in Brazil, set to take place in São Paulo on October 2–3, 2025. The conference is expected to bring together national and international experts, providing physicians with access to hands-on training, certification programs, and the latest insights in regenerative medicine.

“We are hopeful that this event will serve as the first of many collaborative milestones in Brazil,” added Novas. “Our expectation is to create a sustainable platform where education and innovation can come together for the benefit of physicians and their patients.”

---

About Global Stem Cells Group and CELLGENIC
 Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with operations in more than 40 countries. Its divisions cover clinical research, physician education, and biologics commercialization.

Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, platelet-rich plasma kits, and other cellular solutions—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG.

More information:
www.stemcellsgroup.com | www.issca.us

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Former Minister of Health Brings Institutional Leadership to Expand Affiliate Network Across Key Latin American Markets

Las Vegas, Nevada, [July 29, 2025] (ACCESS NEWSWIRE) — Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced the appointment of Dr. José Luis Décima as its new representative for Argentina’s northern region and Paraguay through its Global Stem Cells Group subsidiary. The strategic appointment expands RMTG’s affiliate network into underserved markets with significant growth potential.

Leadership and Market Expansion:

Dr. José Luis Décima, former Minister of Health for the province of Formosa and Director of high-complexity hospitals, brings decades of institutional experience and government healthcare leadership to RMTG’s Latin American expansion. His appointment follows RMTG’s proven affiliate model, where representatives develop regional centers, training programs, and product distribution networks.

“Argentina has played a pivotal role in our history, and now we are ready to take the next step by extending our footprint in the north and into Paraguay,” said David Christensen, CEO of RMTG. “Dr. Décima brings a wealth of experience and institutional knowledge. We expect that his leadership will be instrumental in helping us bring our therapies and educational programs to even more physicians and patients across this important region.”

Strategic Partnership Benefits:

• Institutional Credibility: Former Minister of Health brings government relations expertise and healthcare system knowledge to facilitate market entry and regulatory compliance

• Geographic Expansion: Northern Argentina and Paraguay represent underserved markets with growing demand for advanced regenerative medicine solutions

• Infrastructure Development: Plans already underway for a new regenerative medicine center in Formosa with Dr. Apóstolo and multidisciplinary team, including training programs and clinical care

• Revenue Generation: New territory adds to RMTG’s affiliate and member network spanning 30+ countries, creating multiple revenue streams through training fees, product sales, and certification programs

• ISSCA Integration: Regional representative will develop ISSCA training protocols and certification programs, leveraging RMTG’s proven education platform

Benito Novas, Founder of Global Stem Cells Group, emphasized the historical importance of Argentina in the organization’s growth: “This new alliance with Dr. Décima is the continuation of a trusted relationship — but more importantly, it’s a new beginning for bringing regenerative medicine to underserved areas with integrity and scientific rigor.”

Market Opportunity and Regional Strategy:

The appointment builds on RMTG’s successful Argentina presence, where the Company recently hosted its ISSCA Argentina 2025 event attracting hundreds of medical professionals. Dr. Décima’s government healthcare background provides strategic advantages for navigating regulatory environments and establishing institutional partnerships across the region.

“It is an honor to represent Global Stem Cells Group and ISSCA in Argentina and Paraguay,” said Dr. José Luis Décima. “The development of regenerative medicine in our region has reached a moment of maturity, and now with this alliance, we are prepared to expand that knowledge and structure into concrete action. Our focus will be on education, responsible practice, and innovation.”

The expansion aligns with RMTG’s recent momentum, including Q1 2025 sales of $1.35M representing 67% growth with operational profits of $134,000. The Company expects that its new affiliate program, commencing in Q3, will generate upfront membership fees of up to $500,000, with new members receiving turnkey assistance in setting up regenerative medicine clinics along with continuous training and support.

About RMTG:

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s integrated approach combines clinical operations, product distribution, and medical education to capitalize on the rapidly expanding global regenerative medicine market. To learn more, visit www.stemcellsgroup.com.

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to future revenues, representative appointments, market expansion in Argentina and Paraguay, or development of new regenerative medicine centers. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that Dr. Décima’s appointment will achieve projected benefits, that planned facilities will be successfully developed, or that market opportunities will materialize as anticipated. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contact: David Christensen, CEO and President Regenerative Medical Technologies Group, Inc. investor.relations@regenmedtechgroup.com | (800) 956-3935

Strategic Alliance Adds High-Value Territory to Global Network of 26 Clinics

Las Vegas, Nevada, July 21, 2025 (GLOBE NEWSWIRE) – Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medical solutions, announces its official expansion into Puerto Rico through a newly formed alliance with Dr. Juan C. Ramos and Dr. Aleida G. Nieves at the new “Global Stem Cells Group Puerto Rico.” The partnership was unveiled during a joint press conference led by GSCG’s Founder Benito Novas, RMTG’s CEO Dave Christensen, and the newly appointed representatives for Puerto Rico, Dr. Juan C. Ramos and Dr. Aleida G. Nieves, owners of Global Stem Cells Group Puerto Rico.

Financial Impact:

The Puerto Rico affiliate follows RMTG/GSCG’s proven turnkey model, where new members pay upfront fees in the 6-figure dollar range plus ongoing special supply agreements. Led by Dr. Juan C. Ramos and Dr. Aleida G. Nieves, the partnership establishes Global Stem Cells Group Puerto Rico as a key strategic entry point into Caribbean and Latin American medical markets.

Strategic Partnership Benefits:

• Immediate Revenue Impact: New affiliates generate upfront fees, ongoing fees, plus ongoing exclusive purchases of RMTG’s Cellgenic product line, creating both immediate and recurring revenue streams

• High-Value Market Entry: Puerto Rico’s $4.2 billion healthcare market offers significant growth potential, with U.S. territory status providing regulatory familiarity while maintaining competitive operational costs for medical tourism

• Proven Scalable Model: Partnership replicates RMTG’s successful network framework used across 26 clinics in 21 countries, with turnkey setup reducing risk while ensuring consistent quality standards and brand recognition

• Comprehensive Support Infrastructure: New affiliate receives complete physician training through ISSCA’s world-renowned education platform, ongoing clinical support, marketing assistance, and exclusive access to cutting-edge regenerative medicine protocols

• Strategic Geographic Positioning: Puerto Rico serves as gateway to Latin American markets while maintaining access to U.S. healthcare infrastructure, positioning RMTG for further Caribbean and Central American expansion

The partnership was announced during RMTG/GSCG’s Buenos Aires press conference, where the Company hosted its ISSCA Argentina 2025 conference attracting over 200 medical professionals. Initial plans for Puerto Rico include development of a certified training center, local product distribution network, and the first ISSCA Puerto Rico event scheduled for December 2025.

“We are excited to welcome Dr. Juan C. Ramos and Dr. Aleida G. Nieves as our official representatives for Global Stem Cells Group Puerto Rico,” said David Christensen, CEO and President. “We chose this location because of the extraordinary leadership and commitment we’ve seen in Dr. Juan C. Ramos, Dr. Aleida G. Nieves and their team at Global Stem Cells Group Puerto Rico. This alliance reflects our ongoing mission to bring regenerative medicine to every region where there is both need and readiness to embrace innovation.”

The Puerto Rico expansion builds on RMTG’s recent momentum, including Q1 2025 sales of $1.35M representing 67% growth over last year’s first quarter with operational profits of $134,000. The Company’s affiliate program generates upfront membership fees in the six figure dollar range where new members receive turnkey assistance in setting up regenerative medicine clinics in their area along with continuous training and support. Affiliate members are bound to purchase all supplies exclusively from RMTG, creating sustained recurring revenue streams.

Dr. Juan C. Ramos and Dr. Aleida G. Nieves, who now lead the GSCG Puerto Rico operations, emphasized the impact this collaboration will have on the local medical landscape: “To have the official representation of Global Stem Cells Group in Puerto Rico is a major milestone for us — not just as a clinic, but as contributors to the future of medicine on the island,” said Dr. Ramos. “We now have the opportunity to bring structured, science-based regenerative solutions to the physicians in Puerto Rico, backed by global expertise and a clear ethical framework.”

Benito Novas, Founder of Global Stem Cells Group (GSCG), reflected on the significance of this new chapter: “This is more than just a representation agreement — this is a shared commitment to raising the standard of care in Puerto Rico. From day one, our organization has believed in forming alliances with visionary leaders who are ready to embrace the future of medicine. With Dr. Ramos and Dr. Nieves at Global Stem Cells Group Puerto Rico, we’ve found exactly that.”

About RMTG:

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s affiliate program generates upfront membership fees in the six figure dollar range where new members receive turnkey assistance in setting up regenerative medicine clinics along with continuous training and support.

About ISSCA:


The International Society for Stem Cell Application (ISSCA) serves as the dedicated educational and scientific arm of Global Stem Cells Group. ISSCA is a multidisciplinary, physician-led community composed of medical professionals, researchers, and scientists who are committed to advancing the clinical application of regenerative medicine and cellular therapies. The Society plays a pivotal role in bridging the gap between scientific research and clinical practice by providing a comprehensive platform for education, certification, and international collaboration. Through hands-on training programs, academic conferences, and ongoing professional development, ISSCA promotes the responsible, ethical, and evidence-based use of stem cell protocols across the globe. Its mission is to elevate standards of care and empower healthcare providers to deliver innovative regenerative solutions to their patients.

More information: https://www.issca.us/#

About Global Stem Cells Group:


Global Stem Cells Group (GSCG) is an international consortium of regenerative medicine entities encompassing clinics, laboratories, academic institutions, and product distributors. Headquartered in the United States, GSCG operates in more than 30 countries, offering a full-spectrum approach to the advancement of cellular medicine. The organization is dedicated to democratizing access to cutting-edge regenerative therapies by integrating scientific research, physician training, and high-quality product development. GSCG’s initiatives are focused on improving patient outcomes while transforming the future of healthcare through innovation, strategic global partnerships, and a strong commitment to education. Its multifaceted infrastructure allows GSCG to support every stage of regenerative practice—from laboratory innovation to bedside application.

More information: www.stemcellsgroup.com or call +1 305 560 5331

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to its future revenues, affiliate partnerships, market expansion, or revenue generation from Puerto Rico operations. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that the Puerto Rico affiliate will achieve projected revenue targets, that market opportunities will materialize as anticipated, or that the affiliate model will continue to be successful. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price

For further information, please contact: investor.relations@regenmedtechgroup.com | (800) 956-3935

Argentina Success Validates Global Education Platform with Major Cancun Event and Six More In-Country Programs Scheduled

Las Vegas, Nevada, July 24, 2025 (ACCESS NEWSWIRE) – Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced the successful completion of its ISSCA Argentina 2025 event in Buenos Aires, which attracted hundreds of doctors and medical professionals to the Four Seasons hotel downtown. The Company also announced seven additional ISSCA training events scheduled for 2025, demonstrating continued momentum in its global physician education platform.

Event Success and Revenue Impact:

The Buenos Aires event represents RMTG’s continued expansion of its ISSCA (International Society for Stem Cell Application) education platform, which generates significant revenue through physician training, certification programs, and product sales. The event featured comprehensive training from theoretical lectures to live clinical practice, with doctors completing certification by working through real-life clinical cases guided by industry experts.

Strategic Training Platform Expansion:

• Proven Demand: Hundreds of physicians filled the Four Seasons hotel, validating market appetite for advanced regenerative medicine training

• Revenue Generation: ISSCA events drive multiple revenue streams including training fees, certification programs, and Cellgenic product sales

• Global Reach: Seven additional events scheduled across key markets including major annual event in Cancun

• Certification Value: Hands-on training with real clinical cases provides premium value proposition for medical professionals

• Product Integration: Cellgenic product line serves as official sponsor, creating direct sales opportunities during training events

“We are grateful for the attendance of some of the best doctors who seek out the latest innovations and come to learn new breakthroughs in regenerative medicine,” said David Christensen, CEO and President. “We filled the 4-Seasons hotel downtown with hundreds of doctors and medical professionals who attended this incredible event.”

Upcoming 2025 ISSCA Event Schedule:

The Company announced Seven additional ISSCA training events for 2025, expanding its global education footprint:

1. Global Event Cancun – September 11^th
2. Brazil – October 2^nd
3. Colombia – October 24^th
4. Cancun 2.0 – November  7^th
5. Saudi Arabia – November  14^th
6. Peru – November 28^th
7. Puerto Rico – December 5^th

“ISSCA is one of the world’s largest and most effective Physician Training in the Regenerative Medical Industry,” said Benito Novas, Founder of Global Stem Cells Group (GSCG). “We are honored and grateful to our whole team for the countless hours and enduring passion to consistently put on the best events in the Regenerative Medical industry.”

The Buenos Aires success builds on RMTG’s recent Q1 2025 performance that delivered $1.35M in sales representing 67% growth with operational profits of $134,000. The Company’s global education platform continues to drive both direct revenue and affiliate partnerships worldwide.

About Regenerative Medical Technologies Group, Inc. (RMTG):

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s integrated approach combines clinical operations and procedures, product and equipment distribution, and medical education to capitalize on the rapidly expanding global regenerative medicine market. To learn more, visit www.stemcellsgroup.com

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to its future revenues, affiliate partnerships, market expansion, or revenue generation from Puerto Rico operations. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that the Puerto Rico affiliate will achieve projected revenue targets, that market opportunities will materialize as anticipated, or that the affiliate model will continue to be successful. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price

For further information, please contact: investor.relations@regenmedtechgroup.com | (800) 956-3935

Miami, Florida– Global Stem Cells Group (GSCG), an established international organization focused on advancing regenerative medicine, is pleased to announce a new strategic collaboration with the Njinsky Medical Centre for the exclusive launch of its CELLGENIC product line in Pakistan. This collaboration represents a significant milestone in what both parties hope will be the broader introduction of regenerative technologies across South Asia and the Middle East.

Through this alliance, the Njinsky Medical Centre will serve as the exclusive distributor of CELLGENIC-branded exosome products in Pakistan, a country recognized as one of the most populous and dynamic healthcare markets in the region. Both organizations are committed to a shared vision: to explore opportunities for innovation, improve accessibility to emerging therapies, and support the responsible and ethical application of regenerative medicine technologies.

---

A Collaborative Framework for Long-Term Development

The five-year distribution agreement outlines a coordinated rollout strategy that includes the introduction of CELLGENIC’s full regenerative medicine product portfolio. The agreement also provides for the development of multiple stem cell and regenerative treatment centers across the country, the organization of four physician training sessions annually, and the establishment of an international medical congress in Pakistan focused on education and awareness in the field of cellular therapies.

“We believe this collaboration may offer a sustainable and scalable model for bringing scientifically grounded regenerative solutions to new markets,” said Benito Novas, CEO of Global Stem Cells Group and founder of CELLGENIC. “Through strategic alignment with local institutions like the Njinsky Medical Centre, we hope to support healthcare professionals by expanding access to training and emerging technologies.”

---

The CELLGENIC Portfolio: A Platform for Innovation

As part of the agreement, the Njinsky Medical Centre will receive access to the complete CELLGENIC product range, including lyophilized and liquid-form exosome therapies. These formulations, developed by GSCG through international research and quality-controlled processes, are based on exosomes derived from human umbilical cord stem cells and are produced in accordance with established industry standards.

While results may vary depending on the clinical application, exosomes are being explored for their potential role in supporting tissue regeneration, managing inflammatory conditions, and contributing to overall cellular communication. CELLGENIC’s products are currently offered for investigational and physician-directed use in countries with relevant regulatory frameworks that allow their application.

Key product features include:

• Sourced from human umbilical cord-derived MSCs
  
  
• Available in both liquid and lyophilized (freeze-dried) formulations
  
  
• Manufactured under rigorous quality assurance protocols
  
  
• Intended for use in professional medical settings under clinical guidance
  
  

---

Njinsky Medical Centre’s Commitment to Local Advancement

As part of the implementation plan, the Njinsky Medical Centre will oversee efforts to meet Pakistan’s regulatory and patient safety standards, while aiming to localize certain stages of production. These efforts are intended to align with national healthcare priorities and ensure the ethical and secure handling of all biological materials.

“We are honored to collaborate with Global Stem Cells Group and to take part in introducing these technologies to our region,” said Syed Asad Ali, Chief Executive at Njinsky Medical Centre. “This agreement provides us with access to training programs, certifications, and a product platform that we hope will support Pakistani healthcare professionals in offering advanced, research-driven options to their patients.”

Njinsky’s long-term goal includes the expansion of CELLGENIC’s presence across Pakistan, and the integration of GSCG’s broader business lines—ranging from biologics to medical equipment and physician training.

Usman Shah, Managing Partner of Njinsky Medical Centre, added: “We expect this collaboration to serve as a gateway for growth, research, and the integration of regenerative care into clinical practice, in ways that are both cost-conscious and medically responsible.”

---

Structured Rollout and Training Initiatives

The official launch of the CELLGENIC product line in Pakistan is anticipated for August 2025, with preliminary activities already underway. These include a series of pilot programs and ISSCA-certified training sessions for selected healthcare professionals. The International Society for Stem Cell Application (ISSCA), the educational division of GSCG, will oversee physician training as part of its continuing education initiatives.

Key upcoming milestones include:

• ISSCA Training Programs – Hands-on certification sessions for Pakistani physicians
  
  
• Pilot Program Implementation – Initial clinical protocols rolled out in selected centers
  
  
• Official Launch Event – High-level medical gathering scheduled for August 2025
  
  
• Regional Outreach – Exploration of expansion opportunities in neighboring markets
  
  

Through these initiatives, both organizations seek to lay the foundation for a robust and sustainable regenerative medicine ecosystem in Pakistan, one that may serve as a reference model for future regional partnerships.

---

About Global Stem Cells Group and CELLGENIC

Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a multi-division biotechnology company with a presence in more than 40 countries. As an international consortium, the company is dedicated to stem cell research, physician education, clinical research, and the commercialization of advanced regenerative products.

The organization brings together several specialized companies under one umbrella to offer innovative patient treatment protocols, hands-on training programs, and regulatory consulting. Its flagship brand, CELLGENIC, includes a broad range of biologic solutions—from exosomes to stem cell kits, collagenase systems, and platelet-rich plasma (PRP) kits—developed to support physicians in the evolving field of regenerative healthcare.

GSCG is committed to expanding access to regenerative medicine worldwide and supports physicians through certification programs, conferences, and scientific collaboration.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/

More information: www.stemcellsgroup.com | www.issca.us

---

About the Njinsky Medical Centre

The Njinsky Medical Centre (also known as the Njinsky Stem Cell Centre) is a Pakistan-based institution dedicated to investigating and applying stem cell and exosome therapies for complex and chronic conditions. With ISO 9001 (Quality Management Systems), ISO 14644 (Cleanroom Standards), ISO 15189 (Medical Laboratory Standards), International Accreditation Forum (IAF), and Institute of Global Certification (IGC), offering globally recognized excellence in regenerative medicine. Njinsky has a GMP compliant ISO-certified, biosafety level-2 laboratories and a team of licensed medical professionals, the Medical Centre operates at the intersection of clinical practice and global research. Njinsky’s mission is to responsibly introduce the most promising international therapies to the local context, supporting recovery and quality of life for patients where conventional treatments may offer limited results.

More information: www.stemcellsgroup.com or call +1 305 560 5331

---

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.